Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Takeda Pharmaceutical

    Jump to

    • DCGI issues safety alert on falsified lymphoma injections from Takeda

      Consumers and patients are advised to be careful and only procure the medical products from authorised sources with proper purchase invoice

    • Takeda Pharmaceutical Co launches hemophilia drug Adynovate

    • Takeda-led COVID-19 plasma treatment enters clinical trial with first patient

    • Takeda Pharmaceutical to cut sales jobs in Japan

    • Takeda Pharmaceutical expands portfolio of rare disease therapies in India

    • CEO says Takeda unlikely to sell OTC drug business

    • Cadila Healthcare rises 6%, to develop chikungunya vaccine

    • Sun Pharma gets US FDA nod for Prevacid generic drug

      Sun Pharmaceutical Industries Ltd said its unit has received US Food and Drug Administration's final approval for the generic version of Prevacid.

    • Sun Pharma shares rise on US acquisition

      Shares in Sun Pharmaceutical Industries, India's most valued drugmaker, rose as much as 2.5 percent after its unit agreed to buy the generic drugs business of US-based URL Pharma from Japan's Takeda Pharmaceutical Co.

    • Advinus, Takeda Pharma initiate drug discovery

      Advinus Therapeutics Ltd (Advinus)and Japanese firm Takeda Pharmaceutical Company Ltd (Takeda) jointly announced today that they have entered into an agreement to initiate a three-year drug discovery collaboration.

    • Cipla, Lupin deny in stake sale talks with Takeda Pharma

      Pharmaceutical companies Cipla and Lupin have both strongly denied that they are in talks with Takeda Pharmaceutical Co to sell stake or part of their business, and have said a newspaper report linking the two with the Japanese firm is "baseless."

    • Takeda eyes pharma business of Cipla, Lupin

      Takeda Pharmaceutical Co, Japan's largest drugmaker, is in talks with Indian generic drugmakers Cipla and Lupin about buying one of the companies' pharmaceutical businesses.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347